NewAmsterdam Pharma Co N.V. (NAMS) — research page

US · us-cm-kg/NASDAQ/NAMS · as of 2026-11-08

Identity and listing

The issuer is NewAmsterdam Pharma Co N.V., listed on NASDAQ under ticker NAMS, with ISIN USN625091095. The LEI is not on the record (no GLEIF record with the exact legal name in jurisdiction US-P7). The security type is Corporate, the segment is not on the record, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is Netherlands. The issuer is listed and not halted.

The disclosure read

The record holds 81 filings in the twelve months from 2025-11-08 to 2026-11-08, across 53 filing days. The median gap between filing days is 4.0 days. The latest filing is dated 2026-11-05, a regulatory_filing, 3 days before the record date. The NASDAQ median for filings is 52, the median cadence gap is 6.0 days, and the median latency is 5.0 days. The sector median for filings is 63.0, the median cadence gap is 6.0 days, and the median latency is 4.0 days.

window 2025-11-08 to 2026-11-08 · the node's disclosure lines, as get_filings serves them

Auditor

The auditor is not on the record (no dei:AuditorName tag on the latest annual report cover; foreign private issuers and older filings carry none). The auditor location is not on the record. The record holds no auditor changes.

Events and halts

The record holds no listing, delisting or name change lines. The domicile change is not on the record (EDGAR states no dated change of state of incorporation on a filing line). The segment move is not on the record (the exchanges' tier transfers are not EDGAR filings). The halt flag is listed, not halted.

Orderability

The outcome is not determinable: the chapter's orderability section carries no client_categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, with the chapter as of 2026-11-04.

rule acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability

Coverage

The issuer's own investor-relations page names 17 research houses: BMO Capital Markets, Cantor Fitzgerald & Co., Citi, Goldman Sachs & Co. LLC, Guggenheim Securities, LLC, H.C. Wainwright, Jefferies, Leerink Partners, Needham & Company, LLC, Piper Sandler & Co, RBC Capital Markets, Stifel, TD Cowen, Truist Securities, Van Lanschot Kempen, Wells Fargo, and William Blair & Company.

Open research

The record holds no openly published research notes. None was found.

Licensed

Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.

As-of depth

The issuer's years sealed are 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12. The market's vintage is sealed.

Sources

8 source pages are named on this page; every value above carries its own source page and read date in the numbers.

10.1

https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)

10.2

https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)

10.3

https://data.sec.gov/submissions/CIK0001936258.json (identity.jurisdiction)

10.4

https://mcp.us-cm-kg.ai/events/NASDAQ/NAMS (the disclosure lines)

10.5

https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)

10.6

https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)

10.7

https://ir.newamsterdampharma.com/stock-information/analyst-coverage (coverage)

10.8

https://mcp.us-cm-kg.ai/record/NASDAQ/NAMS (the record)

Read it by agent

The same page, signed and receipted: get_research at https://mcp.getissuer.ai/mcp with {"isin":"USN625091095"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:2ede10568731ce53.